Contribution: Industrial Research Assistance Program – Contributions to Firms
Ripple Therapeutics Corp.
$22,984.00
Sustained release form targeting wet age-related macular degeneration
EF 2022-23 · 2022-09-01
Résumé
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Scientific and engineering resources will perform work on
the development of a novel compound for the treatment of Neovascular age-related macular degeneration (nAMD). The project will require synthesizing novel compounds and performing materials characterization and in vitro evaluations to assess for potential lead compounds for the next stages of development.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
760459073
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2023-01-31
Agreement Number
995494
Agreement Start Date
2022-09-01
Agreement Title
Sustained release form targeting wet age-related macular degeneration
Agreement Title (French)
Forme à libération prolongée ciblant la dégénérescence maculaire exsudative liée à l'âge
Agreement Type
Contribution
Agreement Value
$22,984.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Scientific and engineering resources will perform work on
the development of a novel compound for the treatment of Neovascular age-related macular degeneration (nAMD). The project will require synthesizing novel compounds and performing materials characterization and in vitro evaluations to assess for potential lead compounds for the next stages of development.
Description (French)
Ripple Therapeutics Corporation est une entreprise privée en phase clinique qui se concentre sur les thérapies ophtalmiques avec une libération de médicaments contrôlable et durable. Les ressources scientifiques et d'ingénierie travailleront à la préparation d'un nouveau composé pour le traitement de la dégénérescence maculaire néovasculaire liée à l'âge. Le projet nécessitera la synthèse de nouveaux composés et la réalisation de la caractérisation des matériaux et d'évaluations in vitro afin d'évaluer les composés principaux potentiels pour les prochaines étapes du développement.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
32541
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
760459073
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Ripple Therapeutics Corp.
Recipient Operating Name
Ripple Therapeutics
Recipient Postal Code
M5G 1L7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2022-2023-Q2-995494
